文献速递分子诊断临床免疫

CAR-T细胞治疗导致HIV-1核酸检测假阳性

False-Positive Results for Human Immunodeficiency Virus Type 1 Nucleic Acid Amplification Testing in Chimeric Antigen Receptor T Cell Therapy.
PubMed 文献 · J Clin Microbiol · 2019-12-23

本文报道三例接受CAR-T细胞治疗的患者在常规HIV-1筛查中,第四代酶免疫测定阴性,但Roche Cobas AmpliPrep/Cobas TaqMan HIV-1试验v2.0(靶向gag和长末端重复序列)呈阳性,改用靶向整合酶基因的Abbott m2000 RealTime HIV-1试验复检为阴性,提示慢病毒载体与LTR基因组交叉反应导致假阳性。

要点

  • CAR-T治疗后HIV-1 NAAT假阳性与慢病毒载体和LTR交叉反应有关
  • 第四代HIV筛查阴性而NAAT阳性时应警惕CAR-T相关假阳性
  • 采用靶向整合酶基因的HIV-1 NAAT复检可帮助排除假阳性

核心结论

  • 慢病毒载体与HIV-1 NAAT靶向的LTR基因组交叉反应可导致CAR-T细胞治疗后HIV-1 NAAT假阳性。

研究设计与样本

  • 本文描述三例接受CAR-T细胞免疫治疗患者的临床场景,涉及常规传染病筛查或职业暴露后风险评估。

主要发现

  • 三例患者第四代HIV-1筛查酶免疫测定(靶向p24抗原和抗HIV-1抗体)均为阴性。
  • 三例患者Roche Cobas AmpliPrep/Cobas TaqMan HIV-1试验v2.0(靶向gag和LTR)均为阳性。
  • 上述样本改用Abbott m2000 RealTime HIV-1试验(靶向整合酶基因)复检均为阴性。

临床怎么用

  • CAR-T治疗后HIV-1 NAAT阳性而第四代筛查阴性时,应考虑慢病毒载体相关假阳性可能。
  • 可选用靶向整合酶基因的HIV-1 NAAT进行复检以协助鉴别假阳性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chimeric antigen receptor (CAR) T cell immunotherapy has been a major advancement in cancer therapeutics. Reprogramming of T cells is achieved by using gammaretroviral or lentiviral vectors, which may interfere with human immunodeficiency virus type 1 (HIV-1) nucleic acid amplification testing (NAAT). Here, we describe three clinical scenarios in which CAR T cell immunotherapy interfered with HIV-1 testing, including (i) routine infectious disease screening prior to stem cell transplantation in a 16-year-old female with B cell acute lymphoblastic leukemia, post CAR T cell treatment; (ii) routine infectious disease screening prior to second CAR T cell collection in a 65-year-old male with diffuse large B cell lymphoma who failed initial CAR T cell treatment; and (iii) routine infectious risk assessment following an occupational health exposure from a 58-year-old male with multiple myeloma, who received CAR T cell treatment. In each case, patients initially tested negative by the "fourth-generation" HIV-1 screening enzyme immunoassay (targeting the p24 antigen and anti-HIV-1 antibodies), but positive by the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 test v2.0 (targeting gag and the long terminal repeat [LTR]). These samples subsequently retested negative using the Abbott m2000 RealTime HIV-1 assay, which targets the integrase gene. These results indicated that cross-reactions between lentiviral vectors and LTR genomes targeted in the HIV-1 NAAT caused the HIV-1 NAAT false-positive results.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Hauser JR, Hong H, Babady NE, et al. False-Positive Results for Human Immunodeficiency Virus Type 1 Nucleic Acid Amplification Testing in Chimeric Antigen Receptor T Cell Therapy. J Clin Microbiol. 2019. PMID: 31694968. doi:10.1128/JCM.01420-19

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。